LOW MOLECULAR WEIGHT HEPARIN ENIXUM IN THE PREVENTION AND TREATMENT OF THROMBOSIS IN ONCOLOGY CLINIC
https://doi.org/10.17238/PmJ1609-1175.2019.1.56-60
Abstract
Objective: Oncological patients are at high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and occupy one of the leading places among the causes of death. The aim of this study was to evaluate the efficacy and safety of the use of anticoagulant direct action of domestic production of Enixum (enoxaparin sodium) for the prevention and treatment of thrombosis in cancer patients. Methods: The system of hemostasis and the frequency of thrombotic complications in 210 oncological and gynecological patients undergoing surgical treatment were studied. 80 people (group 1) received Enixum for 7-15 days of the postoperative period. Group 2 (130 people) - patients who did not receive medication prophylaxis of thrombotic complications (control group). Also, 30 oncological patients with acute thrombosis and pulmonary embolism, were studied. Results: The use of low molecular weight heparin Enixum in the postoperative period and in patients with acute thrombosis and pulmonary embolism significantly reduces the intensity of intravascular coagulation, the frequency of venous thrombosis and prevents fatal thromboembolism, which expands the possibilities of anticancer treatment and improves the quality of life of cancer patients. Conclusions: Enixum is an effective and safe drug for the prevention and treatment of thrombosis in oncology clinic.
About the Authors
O. V. Somonova
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Russian Federation
A. L. Elizarova
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Russian Federation
V. N. Blindar
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Russian Federation
M. B. Dobrovolskaya
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Russian Federation
Yu. A. Nesterova
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Russian Federation
References
1. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. 2015. Т. 9, № 4, вып. 2. С. 2-52
2. Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer // Journal of Thrombosis and Haemostasis. 2011. Vol. 9 (Suppl. 1). P. 316-324.
3. Amin C., Mackman N., Key N.C. Microparticles and cancer // Pathophysiol. Haemost. Thromb. 2008. Vol. 36. P. 177-183.
4. Barsam S.J., Patel R., Arya R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism // BJH. 2013. Vol. 161, No. 6. P. 764-777.
5. Franchini M., Bonfanti C., Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants // Thrombosis Research. 2015. Vol. 135, No. 5. P. 777-781.
6. Guyatt G.H., Akl E.A., Growther M. [et al.]. Executive Summary. Antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines // Chest. 2012. Vol. 141, No. 2 (Suppl.). P. 7S-47S.
7. Kakkar A.K., Haas S., Walsh D. [et al.]. Prevention of perioperative venous thromboembolism: Outcome after cancer and non-cancer surgery (abstract) // Thromb. Haemost. 2001. Vol. 86 (Suppl.). P. 0c1732.
8. Kearon C., Akl E.A., Ornelas J. [et al.]. Antithrombotic therapy for VTE disease // Chest. 2016. Vol. 149, No. 2. P 315-352.
9. Kuderer N.M., Lyman G.H. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer // Thromb. Res. 2014. Vol. 133 (Suppl. 2). P S122-S127.
10. Lee A.Y. The roles of anticoagulants in patients with cancer // Thromb. Res. 2010. Vol. 125 (Suppl. 2). P. S8-S11.
11. Lyman G.H., Bohlke K., Khorana A.A. [et al.]. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update 2014 // J. Clin. Oncol. 2015. Vol. 33. Р 654-656.
12. Magnus N., D’Asti E., Meehan B. [et al.]. Oncogenes and the coagulation system - forses that modulate dormant and aggressive states in cancer // Thrombosis Research. 2014. Vol. 133 (Suppl. 2). P. S1-S9.
13. Mandala M. Management ofvenous thromboembolism in cancer patients. ESMO Clinical Practice Guidelines // Ann. Oncol. 2011. Vol. 22 (Suppl. 6). P. vi85-vi92.
14. Trousseau A. Phlegmasia alba dolens // Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. London: New Sydenham Society, 1872. P 281-295.
15. Watson H.G., Keeling D.M., Laffan M. [et al.]. Guedeline on aspects ofcancer-related venous thrombosis // BJH. 2015. Vol. 170, No. 5. P. 640-648.
Review
For citations:
Somonova O.V., Elizarova A.L., Blindar V.N., Dobrovolskaya M.B., Nesterova Yu.A. LOW MOLECULAR WEIGHT HEPARIN ENIXUM IN THE PREVENTION AND TREATMENT OF THROMBOSIS IN ONCOLOGY CLINIC. Pacific Medical Journal. 2019;(1):56-60. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.1.56-60
Views:
611
Email this article 